This receptor, HER-2, is a transmembrane tyrosine kinase that is overexpressed in 15–20% of breast cancers and was associated with aggressive biology and bad prognosis before the era of anti-HER2 therapies emerged one of the most clinically validated targets in breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.